MYH9 and hepatocellular carcinoma: ENKUR, in turn, acts to antagonize the β-catenin/Jun proto-oncogene, AP-1 transcription factor subunit/myosin heavy chain 9/ubiquitin specific peptidase 7 (β-catenin/c-Jun/MYH9/USP7) pathway, leading to increased degradation of c-Myc ubiquitin and suppresses malignant activities of HCC [207].